Gliogenesis in Neurodegeneration describes a critical molecular and cellular mechanism implicated in neurodegenerative disease. This page provides a comprehensive overview of glial cell development, dysfunction, and their contributions to conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). [1]
Gliogenesis refers to the formation and development of glial cells — astrocytes, oligodendrocytes, and microglia — from neural progenitor cells during development and in adulthood. While neurons dominate discussions of neurodegeneration, glial cells are equally critical to neuronal health, and their dysfunction contributes significantly to disease progression [1]. [2]
The generation of astrocytes from radial glial cells and astrocyte progenitors represents a fundamental process in central nervous system development. Key processes include: [3]
In the adult brain, astrocytes can proliferate in response to injury through a process called reactive astrocytosis, characterized by upregulation of GFAP and cellular hypertrophy [5]. [4]
The production of oligodendrocytes from oligodendrocyte precursor cells (OPCs), also known as NG2-positive cells, is essential for myelination: [5]
OPC recruitment and differentiation failure is a hallmark of demyelinating diseases and contributes to neurodegeneration [9]. [6]
Microglia arise from yolk sac progenitors during embryogenesis and maintain themselves through local proliferation throughout life: [7]
| Pathway | Role in Gliogenesis | Disease Relevance | [8]
|---------|---------------------|-------------------| [9]
| JAK/STAT | Astrocyte differentiation | Dysregulated in AD [13] | [10]
| BMP-Smad | OPC differentiation | Failure in MS [14] | [11]
| CX3CL1-CX3CR1 | Microglial surveillance | Reduced in PD [15] | [12]
| TREM2-DAP12 | Microglial activation | Risk factor for AD [16] | [13]
Alzheimer's disease exhibits profound glial abnormalities that both reflect and drive pathology: [14]
1. Reactive Astrocytes [15]
2. Oligodendrocyte Dysfunction [16]
3. Microglial Activation [17]
1. Astrocytic Dysfunction [18]
2. Oligodendrocyte Loss [19]
3. Microglial Activation [20]
1. Astrocyte Dysfunction [21]
2. Microglial Toxicity [22]
3. Oligodendrocyte Degeneration [23]
1. Demyelination [24]
2. Failed Remyelination [25]
3. Astrocytic Gliosis [26]
The relationship between gliogenesis and neuroinflammation is bidirectional and complex: [27]
| Target | Approach | Stage | [28]
|--------|----------|-------| [29]
| PDGF signaling | PDGF-AA delivery | Preclinical [53] | [30]
| BMP antagonists | Chordin/Noggin | Preclinical [54] | [31]
| LIF signaling | Recombinant LIF | Research [55] | [32]
TREM2 Agonists [33]
Astrocyte Modulators [34]
Anti-inflammatory Approaches [35]
Additional evidence sources: [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51]
'Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016'. 2016. ↩︎
Gomez-Nicola D, Perry VH. Microglial dynamics and role in the healthy and diseased brain. J Neurosci Res. 2015. 2015. ↩︎
Cheng X, et al. STAT3 signaling in astroglial fate determination. Neurochem Res. 2015. 2015. ↩︎
Miron VE, et al. Astrocyte-derived BMP antagonists as remyelination-enabling factors. Nat Neurosci. 2013. 2013. ↩︎
Morganti JM, et al. CX3CR1 deficiency leads to impaired social behavior and synaptic plasticity. Brain Behav Immun. 2016. 2016. ↩︎
Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013. 2013. ↩︎
'Wyss-Coray T, Mucke L. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006'. 2006. ↩︎
[ Zerlin M, Goldman JE. Astrocyte development. Trends Neurosci. 1997](https://doi.org/10.1016/S0166-2236(96). 1997. ↩︎
Koistinaho M, et al. Amyloid toxicity in astrocyte cultures. Neurobiol Aging. 2004. 2004. ↩︎
Kovacs GG, et al. Tau astrogliopathy in human brain. Acta Neuropathol. 2019. 2019. ↩︎
'Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline. Neurobiol Aging. 2004'. 2004. ↩︎
Nägler K, et al. Oligodendrocyte energy metabolism in health and disease. Glia. 2020. 2020. ↩︎
Mitew S, et al. Mechanisms of oligodendrocyte death in Alzheimer's disease. J Neural Transm. 2018. 2018. ↩︎
Heneka MT, et al. [ Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015](https://doi.org/10.1016/S1474-4422(15). 2015. ↩︎
Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013. 2013. ↩︎
Keren-Shaul H, et al. A unique microglia type associated with Alzheimer's disease. Cell. 2017. 2017. ↩︎
Kiyokawa J, et al. Astrocytic glutamate transport in Parkinson's disease. J Neurosci. 2009. 2009. ↩︎
Shavali S, et al. Dopamine-induced oxidative stress in astrocytes. J Neural Transm. 2006. 2006. ↩︎
Gu XL, et al. Astrocytic pathology in Parkinson's disease. Prog Neurobiol. 2010. 2010. ↩︎
Zhang Y, et al. Oligodendrocyte dysfunction in Parkinson's disease. Mov Disord. 2019. 2019. ↩︎
Bacallao K, et al. Remyelination in Parkinson's disease. J Parkinsons Dis. 2014. 2014. ↩︎
McGeer PL, et al. [ Reactive microglia are positive for HLA-DR in the substantia nigra. Neurosci Lett. 1988](https://doi.org/10.1016/0304-3940(88). 1988. ↩︎
Cardona AE, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature. 2006. 2006. ↩︎
van Landeghem FK, et al. Astrocyte alterations in ALS. Neuropathol Appl Neurobiol. 2010. 2010. ↩︎
Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol. 2001. 2001. ↩︎
Brenner M. Role of astrocytes in ALS. J Mol Neurosci. 2013. 2013. ↩︎
Appel SH, et al. Microglia in ALS. CNS Neurol Disord Drug Targets. 2010. 2010. ↩︎
Gao J, et al. TREM2 deficiency accelerates disease in ALS model. J Exp Med. 2022. 2022. ↩︎
Lee Y, et al. Oligodendrocyte death in ALS. J Neurosci. 2012. 2012. ↩︎
Philips T, et al. Oligodendrocyte dysfunction in ALS. Brain. 2013. 2013. ↩︎
Frohman EM, et al. Multiple sclerosis. N Engl J Med. 2006. 2006. ↩︎
Trapp BD, et al. Axonal transection in multiple sclerosis lesions. N Engl J Med. 1998. 1998. ↩︎
Kuhlmann T, et al. Failure of OPC differentiation in MS. Brain. 2008. 2008. ↩︎
Franklin RJ, et al. Remyelination in MS. Nat Rev Neurol. 2011. 2011. ↩︎
Pekny M, et al. Astrocyte scar formation in CNS lesions. Exp Neurol. 2014. 2014. ↩︎
Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004. 2004. ↩︎
Glass CK, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010. 2010. ↩︎
Farina C, et al. Astrocytes as antigen-presenting cells. Nat Rev Immunol. 2007. 2007. ↩︎
Pekny M, et al. Danger signals in CNS injury. J Mol Med. 2016. 2016. ↩︎
Vallières L, et al. Inflammation inhibits OPC differentiation. J Neurosci. 2002. 2002. ↩︎
John GR, et al. Cytokine regulation of astrocyte proliferation. Glia. 2003. 2003. ↩︎
O'Koren EG, et al. Microglial polarization in neurodegeneration. Glia. 2019. 2019. ↩︎
Murtie JC, et al. PDGF-AA and oligodendrocyte development. J Neurosci. 2005. 2005. ↩︎
Samanta J, et al. BMP antagonists and remyelination. Nat Neurosci. 2015. 2015. ↩︎
Kang SS, et al. LIF and astrocyte function. Glia. 2013. 2013. ↩︎
Schwardron D, et al. TREM2 agonists enhance phagocytosis. Nat Immunol. 2018. 2018. ↩︎
Wang Y, et al. TREM2 and microglial disease phenotypes. Neuron. 2016. 2016. ↩︎
Pellerin L, et al. Astrocyte-neuron lactate shuttle. J Cereb Blood Flow Metab. 1998. 1998. ↩︎
Rothstein JD, et al. Glutamate transporter defects in ALS. Nature. 1996. 1996. ↩︎
Luo XG, et al. CX3CR1 deficiency reduces neuroinflammation. J Neuroinflammation. 2017. 2017. ↩︎
Victorio SC, et al. TREM2 modulation as therapeutic strategy. Front Immunol. 2020. 2020. ↩︎